Literature DB >> 23473352

Monoamine oxidase inhibitors revisited: what you should know.

Joseph F Goldberg1, Michael E Thase.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23473352     DOI： 10.4088/JCP.12ac08299

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  7 in total

Review 1.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

2.  Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.

Authors:  Hamlin Emory; Neptune Mizrahi
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

Review 3.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

4.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

Review 5.  Current place of monoamine oxidase inhibitors in the treatment of depression.

Authors:  Kenneth I Shulman; Nathan Herrmann; Scott E Walker
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 6.  Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.

Authors:  John P M Finberg; Jose M Rabey
Journal:  Front Pharmacol       Date:  2016-10-18       Impact factor: 5.810

7.  Higher patient satisfaction with antidepressants correlates with earlier drug release dates across online user-generated medical databases.

Authors:  Scott Siskind; Roland C Aydin; Punit Matta; Christian J Cyron
Journal:  Pharmacol Res Perspect       Date:  2017-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.